Search Results

You are looking at 1 - 6 of 6 items for :

  • "paronychia" x
  • All content x
Clear All
Full access

Barbara Burtness, Milan Anadkat, Surendra Basti, Miranda Hughes, Mario E. Lacouture, Joan S. McClure, Patricia L. Myskowski, Jennifer Paul, Clifford S. Perlis, Leonard Saltz, and Sharon Spencer

health-related quality of life and implications for clinical management of psychological sequelae . Oncology (Williston Park) 2007 ; 21 ( 11 Suppl 5 ): 34 – 36 . 29 Lacouture ME Lai SE . The PRIDE (papulopustules and/or paronychia

Full access

Mario E. Lacouture

survival times among patients with grade 3 rash. 1 Acne-like rash emerges first, followed by postinflammatory effects such as dry skin, fissures in palms and soles, and paronychia (nail changes). Unfortunately, surveys have shown a high rate of

Full access

Barbara Burtness

nitrate have been used to improve these conditions, she added. The nail disease paronychia is the result of a bacterial, viral, or fungal infection; Dr. Burtness emphasized the role of culturing these infections and appropriately administering oral

Full access

Presenters: Dara L. Aisner and Gregory J. Riely

-free survival in stage IB–IIIA disease,” Dr. Riely stated. “Time will tell if it improves OS,” he added. Adverse events associated with osimertinib include diarrhea, paronychia, dry skin, pruritis, cough, and stomatitis. The rates of grades 3 and 4 adverse

Full access

William J. Gradishar, Benjamin O. Anderson, Jame Abraham, Rebecca Aft, Doreen Agnese, Kimberly H. Allison, Sarah L. Blair, Harold J. Burstein, Chau Dang, Anthony D. Elias, Sharon H. Giordano, Matthew P. Goetz, Lori J. Goldstein, Steven J. Isakoff, Jairam Krishnamurthy, Janice Lyons, P. Kelly Marcom, Jennifer Matro, Ingrid A. Mayer, Meena S. Moran, Joanne Mortimer, Ruth M. O'Regan, Sameer A. Patel, Lori J. Pierce, Hope S. Rugo, Amy Sitapati, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, Erica M. Stringer-Reasor, Melinda L. Telli, John H. Ward, Jessica S. Young, Jennifer L. Burns, and Rashmi Kumar

paronychia (30%, 0%, 15%). The NCCN panel has also included other combinations of available endocrine therapies such as fulvestrant or tamoxifen with trastuzumab as options for HR-positive and HER2-positive metastatic disease. These options would be mostly

Full access

Gary R. Hudes, Michael A. Carducci, Toni K. Choueiri, Peg Esper, Eric Jonasch, Rashmi Kumar, Kim A. Margolin, M. Dror Michaelson, Robert J. Motzer, Roberto Pili, Susan Roethke, and Sandy Srinivas

toxicities associated with targeted therapies for advanced kidney cancer vary, but can include rash, paronychia, pruritus, yellowing of skin, and hair depigmentation. 128 An important part of the management plan is educating patients about the likelihood of